Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hebart, H; Klingspor, L; Klingebiel, T; Loeffler, J; Tollemar, J; Ljungman, P; Wandt, H; Schaefer-Eckart, K; Dornbusch, HJ; Meisner, C; Engel, C; Stenger, N; Mayer, T; Ringden, O; Einsele, H.
A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.
Bone Marrow Transplant. 2009; 43(7): 553-561.
Doi: 10.1038/bmt.2008.355
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Dornbusch Hans Jürgen
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We compared the efficacy and safety of empirical plus PCR-based vs empirical liposomal amphotericin B treatment after Allo-SCT. Allo-SCT recipients were randomized to receive either PCR-based preemptive therapy (group A; n=198) or empirical antifungal therapy (group B; n=211) with liposomal amphotericin B. In group A, therapy was started after one positive PCR result or after 120 h of febrile neutropenia refractory to broad-spectrum antibacterial therapy. In group B, liposomal amphotericin B was started after 120 h of refractory febrile neutropenia. Demographic and clinical characteristics were well balanced. A total of 112 (57.1%) patients in group A and 76 (36.7%) patients in group B received antifungal therapy (P<0.0001). Twelve patients in group A and 16 patients in group B developed proven invasive fungal infection (IFI). Survival curves showed better survival until day 30 when close PCR monitoring was performed (mortality 1.5 vs 6.3%; P=0.015), but there was no difference at day 100. At day 100, no difference was observed in the incidence of IFI (primary end point) and survival between the two arms. Further studies are required to assess the benefit of using PCR in patients after SCT.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Amphotericin B - adverse effects
- Child -
- Child, Preschool -
- Female -
- Humans -
- Infant -
- Liposomes - therapeutic use
- Male -
- Middle Aged -
- Mycoses - drug therapy
- Polymerase Chain Reaction -
- Stem Cell Transplantation - adverse effects
- Survival Analysis -
- Transplantation, Homologous -
- Find related publications in this database (Keywords)
- liposomal amphotericin B
- antifungal therapy
- allogeneic BMT
- Allo-SCT
- PCR-based treatment
- fungal infections